Publications

Found 15 results
Filters: First Letter Of Last Name is C and Author is Chan, Albert H  [Clear All Filters]
2015
Lee, W. - G., Frey, K. M., Gallardo-Macias, R., Spasov, K. A., Chan, A. H., Anderson, K. S., and Jorgensen, W. L. (2015) Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 25, 4824-4827
2016
Kattke, M. D., Chan, A. H., Duong, A., Sexton, D. L., Sawaya, M. R., Cascio, D., Elliot, M. A., and Clubb, R. T. (2016) Crystal Structure of the Streptomyces coelicolor Sortase E1 Transpeptidase Provides Insight into the Binding Mode of the Novel Class E Sorting Signal. PLoS One. 11, e0167763
Lee, W. - G., Chan, A. H., Spasov, K. A., Anderson, K. S., and Jorgensen, W. L. (2016) Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents. ACS Med Chem Lett. 7, 1156-1160
2017
Chan, A. H., Lee, W. - G., Spasov, K. A., Cisneros, J. A., Kudalkar, S. N., Petrova, Z. O., Buckingham, A. B., Anderson, K. S., and Jorgensen, W. L. (2017) Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography. Proc Natl Acad Sci U S A. 10.1073/pnas.1711463114
Kudalkar, S. N., Beloor, J., Chan, A. H., Lee, W. - G., Jorgensen, W. L., Kumar, P., and Anderson, K. S. (2017) Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection. Mol Pharmacol. 91, 383-391
2019
Kudalkar, S. N., Ullah, I., Bertoletti, N., Mandl, H. K., Cisneros, J. A., Beloor, J., Chan, A. H., Quijano, E., W Saltzman, M., Jorgensen, W. L., Kumar, P., and Anderson, K. S. (2019) Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV. Antiviral Res. 167, 110-116
Bertoletti, N., Chan, A. H., Schinazi, R. F., Y Yin, W., and Anderson, K. S. (2019) Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. Protein Sci. 28, 1664-1675
2020
Bertoletti, N., Chan, A. H., Schinazi, R. F., and Anderson, K. S. (2020) Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance. Molecules. 10.3390/molecules25204868
Duong, V. N., Ippolito, J. A., Chan, A. H., Lee, W. - G., Spasov, K. A., Jorgensen, W. L., and Anderson, K. S. (2020) Structural investigation of 2-naphthyl phenyl ether inhibitors bound to WT and Y181C reverse transcriptase highlights key features of the NNRTI binding site. Protein Sci. 10.1002/pro.3910
2021
Tran, T. H., Chan, A. H., Young, L. C., Bindu, L., Neale, C., Messing, S., Dharmaiah, S., Taylor, T., Denson, J. - P., Esposito, D., Nissley, D. V., Stephen, A. G., McCormick, F., and Simanshu, D. K. (2021) KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation. Nat Commun. 12, 1176
2022
Frey, K. M., Bertoletti, N., Chan, A. H., Ippolito, J. A., Bollini, M., Spasov, K. A., Jorgensen, W. L., and Anderson, K. S. (2022) Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase. Front Mol Biosci. 9, 805187
2023
Hollander, K., Chan, A. H., Frey, K. M., Hunker, O., Ippolito, J. A., Spasov, K. A., Yeh, Y. - H. J., Jorgensen, W. L., Ho, Y. - C., and Anderson, K. S. (2023) Exploring novel HIV-1 reverse transcriptase inhibitors with drug-resistant mutants: A double mutant surprise. Protein Sci. 32, e4814
Chao, F. - A., Chan, A. H., Dharmaiah, S., Schwieters, C. D., Tran, T. H., Taylor, T., Ramakrishnan, N., Esposito, D., Nissley, D. V., McCormick, F., Simanshu, D. K., and Cornilescu, G. (2023) Reduced dynamic complexity allows structure elucidation of an excited state of KRAS. Commun Biol. 6, 594
2024
Maciag, A. E., Stice, J. P., Wang, B., Sharma, A. K., Chan, A. H., Lin, K., Singh, D., Dyba, M., Yang, Y., Setoodeh, S., Smith, B. P., Ju, J. Hyun, Jeknic, S., Rabara, D., Zhang, Z., Larsen, E. K., Esposito, D., Denson, J. - P., Ranieri, M., Meynardie, M., Mehdizadeh, S., Alexander, P. A., Blanco, M. Abreu, Turner, D. M., Xu, R., Lightstone, F. C., Wong, K. - K., Stephen, A. G., Wang, K., Simanshu, D. K., Sinkevicius, K. W., Nissley, D. V., Wallace, E., McCormick, F., and Beltran, P. J. (2024) Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C. Cancer Discov. 10.1158/2159-8290.CD-24-0840
2025
Alexander, P., Chan, A. H., Rabara, D., Swain, M., Larsen, E. K., Dyba, M., Chertov, O., Ashraf, M., Champagne, A., Lin, K., Maciag, A., Gillette, W. K., Nissley, D. V., McCormick, F., Simanshu, D. K., and Stephen, A. G. (2025) Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraints. J Biol Chem. 10.1016/j.jbc.2025.110331